Personalized brain- circuit based approach to pramipexole in depression
Official title: Stratified Pharmacological Approaches for Regulating Circuit-Level Effects Study
Run by Stanford University · NCT07022405 · Data updated 2026-11-12
This study tests whether pramipexole helps people with major depressive disorder based on specific brain circuit activity.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Palo Alto, California) |
| Status | Recruiting |
| Started | January 23, 2026 |
| Main results expected | August 2030 |
| Study ends | August 2030 |
| Registry record updated | May 15, 2026 |
| Trial ID | NCT07022405 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18-65 with current or recurrent nonpsychotic MDD who can complete an fMRI and consent to the protocol.
✕Probably not a fit
Patients whose depression does not show circuit-based responsiveness to pramipexole or who cannot complete MRI screening may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In this phase 2 trial, researchers will use an 8-week course of pramipexole to see how patients with depression respond and whether brain circuit function predicts who benefits. Participants will undergo a one-time, non-invasive fMRI assessment, complete in-scanner tasks, and provide mood and cognitive information, followed by weekly remote check-ins during treatment and a 2-week taper. The goal is to identify circuit-based factors that relate to treatment response and to move toward personalized medication choices. The study is conducted at Stanford with collaboration from NIMH and is open to adults 18-65 meeting criteria for current or recurrent nonpsychotic MDD.
Why it matters
Potential benefit: If successful, the study could lead to more tailored use of pramipexole for depression based on brain circuitry.
How similar studies have gone: Other trials have explored circuit-informed approaches in mood disorders, but this specific brain-circuit stratification with pramipexole is a newer, exploratory strategy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18-65 years old (inclusive) * Fluent and literate in English, with non-impaired intellectual abilities to ensure adequate comprehension of the task instructions. * Willing to provide written, informed consent. * Functional magnetic resonance imaging (fMRI) scanning eligibility. All participants will need to successfully complete the screening forms at the Stanford Center for Cognitive and Neurobiological Imaging (CNI). * Patient Health Questionnaire-8 (PHQ-8) \>/= 10 * Meet the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria for current or recurrent nonpsychotic Major Depressive Disorder (MDD) established by the Mini International Neuropsychiatric Interview (MINI) Exclusion Criteria: * Suicidality with active plan or as determined clinician judgment * Current or lifetime history of medical illness or brain injury that may interfere with assessments as determined by clinician judgment * Severe impediment to vision, hearing, and/or hand movement likely to interfere with ability to complete the assessments, or is unable and/or unlikely to follow the study protocols as determined by clinician judgment * Pregnant, breastfeeding or unwilling or unable to use adequate birth control throughout the study * History of non-responsive depression to dopamine agonists * Any contraindication to being scanned in the 3.0T fMRI scanner, such as a cardiac pacemaker or implanted device that has not been cleared for scanning * Previous or current DSM-5 bipolar disorder (I, II, not otherwise specified), schizophrenia spectrum or other psychotic disorders, or psychosis or as determined by clinician judgment * Previous or current diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) * Meeting DSM-5 criteria for current Obsessive-Compulsive Disorder (OCD) or eating disorder * Meeting DSM-5 criteria for alcohol use disorder or substance use disorder within the last 12 months * Clinically significant presence/history of impulsive-compulsive behaviors or control disorder including but not limited to gambling disorder within the last 12 months. * Current use or use of psychotropic medication within the past month. (If the participant's usual treating clinician agrees with discontinuing the medication, participants may enroll after tapering off the medication under the supervision of either their usual clinician or the study clinician. A washout period of 5 half-lives-or a different duration as determined by the study clinician-must be completed before the first scan.) * Concurrent participation in other intervention or treatment studies
Where it's running
-
Stanford University
Palo Alto, California, United States Recruiting
Study contacts
- Study coordinator: Isabelle Wydler
- Email: iwydler@stanford.edu
- Phone: (650)-736-4393
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding how the orbitofrontal cortex guides approach vs. avoidance in depression
This study tests how different parts of the orbitofrontal cortex influence whether people pursue rewards or risk loss, and whether this pattern is altered in Major Depressive Disorder.
-
Health education program to help depression in older adults and caregivers in Ho Chi Minh City
A community-based education program for people 60+ and their caregivers is being tested to see if it can lower depression and improve quality of life compared with standard care.
-
Prucalopride for low mood: testing a 5-HT4 receptor activator for cognition and sleep
This study tests whether prucalopride, a 5-HT4 receptor drug, can improve thinking and sleep in adults with low mood or major depressive disorder compared to a placebo.
-
Pre-visit Companion Brief: a primary care AI-assisted check for depression and anxiety
This pilot tests an AI-powered pre-visit assessment that creates a concise Companion Brief for clinicians to help identify depression and anxiety during routine primary care.
-
Medically tailored groceries to help depression in people with food insecurity
This trial tests whether giving medically tailored groceries for six months can reduce depressive symptoms in adults who have depression and struggle with access to food.
-
Health and Work Ability After Inpatient Treatment for Stress-Related Disorders: Follow-Up of the HARMODI Cohort
This study follows people who had inpatient treatment for stress-related disorders to see how their health and ability to work change over the next three years and what factors help them return to work.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.